Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead reveals partial clinical hold on 2 CAR-T trials
Initially a voluntary pause, the clinical trials for KITE-753 have been placed on a partial clinical hold to investigate safety.
Michael Gibney
Oct 30, 2026 10:04am
Gilead to buy PepStar’s oral IL-23 drug for $1.3B upfront
Oct 23, 2026 9:00am
Gilead is ‘sitting on a foundational asset’ with oral UC drug
Oct 19, 2026 9:46am
Vir CEO sees chance ‘to do more deals’ after $1.9B Gilead pact
Oct 14, 2026 8:30am
DPHARM: How to address the clinical trial enrollment crisis?
Sep 17, 2026 11:52am
CEO O’Day tells Fierce how Gilead reached ‘critical mass’
Sep 16, 2026 8:00am